Search Results

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Teon Therapeutics today announced that it has entered into the clinical trial collaboration agreement with Merck (known as MSD outside the United States and Canada), a leader in immuno-oncology (IO).

Gain Therapeutics, Inc. announces that Matthias Alder has departed the Company in order to pursue other opportunities.

Initiates Development of Tailored Innovative Targeted Therapy for Refractory Cancer ReCerise Therapeutics Inc., has announced its selection for a grant from the Ministry of Trade, Industry and Energy of South Korea.

Teon Therapeutics Announces FDA Acceptance of IND Application for Novel, Oral Immune Checkpoint Inhibitor, TT-816.

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced plans to accelerate its development initiatives in obesity and cardiometabolic disease through the acquisition of the assets of Better Therapeutics, Inc.

Teon Therapeutics, a clinical-stage biopharmaceutical company targeting metabolic signaling pathways and pioneering the development of G-Protein Coupled Receptor immuno-oncology therapies in difficult-to-treat cancers, announced the appointment of Serge Messerlian as Chief Executive Officer and member of the board of directors.